Back

Targeted medical treatment based on specific endotype defined by intracoronary physiology testing leads to rapid improvement of quality of life in symptomatic patients with INOCA

29 August 2025 (14:15 - 15:00)
Organised by: Logo
Congress Presentation Part of: Chronic coronary syndromes: MINOCA/INOCA and non-significant coronary artery disease Coronary Microcirculation and Collaterals ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Barbara Vitola

Paul Stradins Clinical University Hospital, Riga (Latvia)

6 More presentations in this session

Presentation thumbnail
Prognostic stratification by coronary flow reserve and left atrial volume index in patients with non-obstructive coronary artery disease
Doctor A. Ito (Yokosuka, JP)
Abstract Slides Video
Presentation thumbnail
Utility of myocardial contrast echocardiography for evaluating microvascular dysfunction in patients with ischemia and non-obstructive coronary arteries
Professor Y. Mu (Urumqi, CN)
Abstract Slides Video
Presentation thumbnail
MINOCA: frequency and clinical features in different LGE-patterns
Doctor E. Tukhsanboev (Dushanbe, TJ)
Abstract Slides Video
Presentation thumbnail
Your heart speaks survey programme - a global survey on the ANOCA patient journey (diagnosis)
Doctor S. La (Adelaide, AU)
Abstract Slides Video
Presentation thumbnail
Basal coronary microvascular resistance predicting death and heart failure in patients without functional coronary stenosis
Doctor I. Saito (Yokosuka, JP)
Abstract Slides Video

Access the full session

Session thumbnail
Chronic coronary syndromes: MINOCA/INOCA and non-significant coronary artery disease

The Event

Event poster

ESC Congress 2025

29 August 2025 14:15 CET
You may be interested in
thumbnail
Congress Session
Diagnosis and treatment of microvascular and epicardial coronary artery disease
thumbnail
Congress Presentation
Endotypes of angina with non-obstructive coronary arteries
thumbnail
Congress Presentation
Improvement of symptoms and quality of life in patients with coronary vasomotion disorders by endotype-based drug therapy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources